Alzheimer’s disease
Eisai and Biogen have completed the rolling submission of a Biologics License Application for lecanemab drug to the U.S. Food and Drug Administration.
A recent study describes how researchers at the UK Research Institute at the University of Cambridge stumbled upon a potential target of dementia research.
Athira Pharma announced the duration of its open-label study of fosgonimeton for the treatment of mild-to-moderate Alzheimer’s Disease (AD) has been increased from six months to eighteen months.
May has been fruitful for research into the prevention and diagnosis of Alzheimer’s disease, the mechanisms behind early symptoms and potential treatments.
Denali Therapeutics, Inc. has announced that dosing has begun for participants of a Phase II clinical trial that intends to evaluate the potential of SAR443820 (DNL788) in patients with amyotrophic lateral sclerosis (ALS).
Speculations that Biogen might appeal the decision after reports of the company hiring several lobbyists, including Clyburn Consulting and Federal Street Strategies.
New research suggests that treatment with anti-amyloid-beta protofibril antibody lecanemab is estimated to slow the rate of disease progression in patients with Alzheimer’s Disease.
Cassava Sciences CEO Remi Barbier is hitting back at The New York Times, calling out the newspaper for an article that he claims misrepresented the research of his company.
Biogen has withdrawn its Marketing Authorization Application (MAA) for European approval of Aduhelm after regulators hinted data was not strong enough to support potential approval.
AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s Disease and other movement disorders.
PRESS RELEASES